Boston Scientific wins big book as Bayer brings hybrid
Boston Scientific Corp, the US medical devices maker, obtained plenty of demand for its €900m bond as it made its debut in the Reverse Yankee market on Wednesday, while the euro corporate bond pipeline continues to fill for a flurry of issuance in November.
Bank of America, Barclays, and Goldman Sachs were bookrunners, and set initial price talk at 95bp over mid-swaps for the eight year issue rated Baa2/BBB-/BBB.
Demand swelled to more than €3bn and guidance was set at 75bp to 80bp.
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org